Stockholm, Sweden — 21 January 2026 — Sigrid Therapeutics (Sigrid) is a Swedish, science-driven consumer health company with a primary focus on metabolic health. Following the successful launch of its first two clinically proven products — Carb Fence, designed to reduce appetite and cravings while supporting fat loss, lean muscle preservation, and post-meal blood sugar control, and Glucose Stabiliser, a dietary supplement designed to help regulate blood sugar after meals — Sigrid today announced that it has entered into an exclusive global licensing and research collaboration with a leading multinational consumer health company to expand the SiPore® technology platform into consumer oral health through a partner-led approach.
“While our primary focus remains the continued commercialization of Carb Fence and Glucose Stabiliser, this partnership allows us to realize additional value from the SiPore® platform through a capital-efficient, non-dilutive approach,” said Sana Alajmovic, Co-Founder and CEO of Sigrid. “It also demonstrates SiPore®’s potential to support multiple large-scale health applications over time and reflects strong validation of the platform following an extensive two-year scientific, technical, and commercial due diligence process conducted by a multinational partner.”
The agreement covers the use of SiPore® across consumer oral health formulations and establishes a framework for joint research and clinical evaluation, with the objective of enabling future commercialization following clinical validation. The collaboration marks an important milestone in the continued development of SiPore® as a platform technology with multiple application areas, pursued in parallel with Sigrid’s ongoing commercialization within metabolic health.
A high-quality partnership structure aligned with long-term value creation
Under the terms of the agreement, Sigrid will receive:
– an upfront payment,
– development and clinical milestones,
– additional sales-based milestone payments, and
– ongoing, long-term royalties on net sales.
The agreement is structured as a multi-year, royalty-bearing partnership, with Sigrid’s participation aligned to the long-term commercial success of SiPore®-based products in global oral health markets. The structure reflects a shared ambition to build durable value through scientific validation and global scale.
A differentiated platform addressing one of the world’s largest everyday health markets
SiPore® is Sigrid’s proprietary, non-systemic material technology platform built on precisely engineered porous silica particles. In oral health, SiPore® acts through a purely mechanical mode of action, binding and removing key proteins and enzymes involved in plaque and biofilm formation in the oral cavity. This enables an immediate and sustained first line of defense against plaque formation and dental caries, without systemic exposure.
Oral diseases — including dental caries and gum disease — are the most common diseases globally, affecting an estimated 3.5 billion people worldwide. The global toothpaste market alone is valued at approximately USD 19 billion annually and is expected to grow to around USD 28 billion by 2034, driven by increasing focus on preventive health, premium formulations, and science-backed daily-use solutions.
Within this context, consumer oral health — particularly the fast-growing mass-premium segment — represents a large and strategically attractive application area for the SiPore® platform, with the potential to support differentiated products at global scale.
“Oral health is a demanding category where safety, efficacy, and daily usability are critical,” said Damir Konakovic, Head of Oral Health at Sigrid. “This collaboration enables rigorous scientific validation of SiPore® in oral health, while leveraging a partner with the capabilities to translate that science into products that can reach consumers globally and at scale.”
About Sigrid Therapeutics (Sigrid)
Sigrid is a Swedish science-driven consumer health company developing novel, non-systemic technologies to address major everyday health challenges. Built around the patented SiPore® platform, Sigrid’s portfolio includes products targeting metabolic health, including Carb Fence and Glucose Stabiliser, with additional applications enabled through strategic partnerships.
Contact information
Sana Alajmovic
Co-Founder & CEO, SIGRID
sana@sigridthx.com
+46 723 893 396
www.sigridthx.com
